Kornitzer Capital Management Inc. KS Has $12.89 Million Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Kornitzer Capital Management Inc. KS increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 10.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,517 shares of the medical research company's stock after purchasing an additional 3,564 shares during the quarter. Kornitzer Capital Management Inc. KS owned about 0.14% of Bio-Rad Laboratories worth $12,887,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BIO. Van ECK Associates Corp acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth approximately $180,040,000. First Eagle Investment Management LLC lifted its position in Bio-Rad Laboratories by 32,296.9% in the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock worth $173,773,000 after purchasing an additional 634,311 shares during the period. Dimensional Fund Advisors LP boosted its stake in Bio-Rad Laboratories by 64.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company's stock valued at $135,081,000 after purchasing an additional 193,700 shares in the last quarter. Select Equity Group L.P. increased its position in shares of Bio-Rad Laboratories by 26.2% during the 2nd quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company's stock valued at $177,391,000 after purchasing an additional 134,856 shares during the period. Finally, Earnest Partners LLC raised its stake in shares of Bio-Rad Laboratories by 30.8% in the 1st quarter. Earnest Partners LLC now owns 514,906 shares of the medical research company's stock worth $178,091,000 after buying an additional 121,272 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Price Performance

BIO traded up $0.34 during trading on Thursday, reaching $373.27. The company had a trading volume of 155,520 shares, compared to its average volume of 195,902. The firm's 50-day simple moving average is $337.07 and its 200 day simple moving average is $310.43. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same period last year, the firm posted $2.33 earnings per share. The firm's quarterly revenue was up 2.8% compared to the same quarter last year. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of the firm's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company's stock, valued at $48,582.03. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares of the company's stock, valued at $48,582.03. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 17.50% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BIO. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Citigroup raised their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 target price on the stock. Finally, Royal Bank of Canada raised their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.